Next Article in Journal / Special Issue
Mirtazapine for the Treatment of Chronic Pruritus
Previous Article in Journal
Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth
Article Menu

Export Article

Open AccessArticle

Chronic Pruritus Responding to Dupilumab—A Case Series

1
Department of Dermatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA
2
Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
3
Drexel University College of Medicine, Philadelphia, PA 19129, USA
4
Department of Dermatology, University of Virginia, Charlottesville, VA 22903, USA
5
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19140, USA
*
Author to whom correspondence should be addressed.
Medicines 2019, 6(3), 72; https://doi.org/10.3390/medicines6030072
Received: 23 May 2019 / Revised: 15 June 2019 / Accepted: 26 June 2019 / Published: 29 June 2019
(This article belongs to the Special Issue Pathogenesis and Treatment of Chronic Pruritus)
  |  
PDF [799 KB, uploaded 10 July 2019]
  |  

Abstract

Background: Chronic pruritus is defined as itch lasting for greater than six weeks. Pruritus is a burdensome manifestation of several internal and external disease states with a significant impact on quality of life. Dupilumab has shown promise in treating a number of conditions including atopic dermatitis (AD) and asthma. Its success in reducing pruritus in AD has generated interest regarding its potential application in other pruritic conditions, such as chronic pruritus of unknown origin, uremic pruritus, and pruigo nodularis. Methods: In this retrospective analysis, we present a series of 20 recalcitrant pruritus patients seen at a tertiary center treated with off-label dupilumab at standard AD dosing. Results: Dupilumab was successful at reducing itch in all treated patients, leading to complete resolution in 12/20 patients and an overall mean NRSi reduction of 7.55. Dupilumab was well tolerated with no significant adverse effects. Conclusions: Our case series suggests dupilumab may be a safe and efficacious therapeutic option in several pruritic conditions and demonstrates the need for further studies to better ascertain its place in the pruritus treatment armamentarium. View Full-Text
Keywords: dupilumab; IL-4; IL-13; pruritus; chronic pruritus of unknown origin; prurigo nodularis; uremic pruritus; lichen planus; eosinophilic dermatosis of hematologic malignancy; chronic pruritus dupilumab; IL-4; IL-13; pruritus; chronic pruritus of unknown origin; prurigo nodularis; uremic pruritus; lichen planus; eosinophilic dermatosis of hematologic malignancy; chronic pruritus
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Zhai, L.L.; Savage, K.T.; Qiu, C.C.; Jin, A.; Valdes-Rodriguez, R.; Mollanazar, N.K. Chronic Pruritus Responding to Dupilumab—A Case Series. Medicines 2019, 6, 72.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top